Skip to main content

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Publication ,  Journal Article
Mesa, RA; Kiladjian, J-J; Verstovsek, S; Al-Ali, HK; Gotlib, J; Gisslinger, H; Levy, R; Siulnik, A; Gupta, V; Khan, M; DiPersio, JF; Knoops, L ...
Published in: Haematologica
February 2014

Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best available therapy [n=73]) from the two phase 3 COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment (COMFORT) studies. Spleen volume was assessed by magnetic resonance imaging/computed tomography at baseline and every 12 weeks through week 72; spleen length was assessed by palpation at each study visit. Health-related quality of life and symptoms were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items at baseline and in weeks 4, 8, 12, 16 and 24 in COMFORT-I and in weeks 8, 16, 24 and 48 in COMFORT-II. The demographic and baseline characteristics were similar between the control arms of the two studies. One patient who received placebo and no patients who received best available therapy had a ≥35% reduction in spleen volume from baseline at week 24. At 24 weeks, neither placebo nor best available therapy had produced clinically meaningful changes in global quality of life or symptom scales. Non-hematologic adverse events were mostly grade 1/2; the most frequently reported adverse events in each group were abdominal pain, fatigue, peripheral edema and diarrhea. These data suggest that non-Janus kinase inhibitor therapies provide little improvement in splenomegaly, symptoms or quality of life as compared with placebo. Both COMFORT-I (NCT00952289) and COMFORT-II (NCT00934544) studies have been appropriately registered with clinicaltrials.gov.

Duke Scholars

Published In

Haematologica

DOI

EISSN

1592-8721

Publication Date

February 2014

Volume

99

Issue

2

Start / End Page

292 / 298

Location

Italy

Related Subject Headings

  • Time Factors
  • Splenomegaly
  • Spleen
  • Quality of Life
  • Protein Kinase Inhibitors
  • Primary Myelofibrosis
  • Organ Size
  • Middle Aged
  • Male
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mesa, R. A., Kiladjian, J.-J., Verstovsek, S., Al-Ali, H. K., Gotlib, J., Gisslinger, H., … Harrison, C. (2014). Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 99(2), 292–298. https://doi.org/10.3324/haematol.2013.087650
Mesa, Ruben A., Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, et al. “Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.Haematologica 99, no. 2 (February 2014): 292–98. https://doi.org/10.3324/haematol.2013.087650.
Mesa RA, Kiladjian J-J, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014 Feb;99(2):292–8.
Mesa, Ruben A., et al. “Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.Haematologica, vol. 99, no. 2, Feb. 2014, pp. 292–98. Pubmed, doi:10.3324/haematol.2013.087650.
Mesa RA, Kiladjian J-J, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014 Feb;99(2):292–298.

Published In

Haematologica

DOI

EISSN

1592-8721

Publication Date

February 2014

Volume

99

Issue

2

Start / End Page

292 / 298

Location

Italy

Related Subject Headings

  • Time Factors
  • Splenomegaly
  • Spleen
  • Quality of Life
  • Protein Kinase Inhibitors
  • Primary Myelofibrosis
  • Organ Size
  • Middle Aged
  • Male
  • Immunology